Brigitte Dreno
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Kempf W, Horwitz S, Prince H, Guitart J, Estrach T, Sanches J, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Berti E, Cerroni L, Pfaltz K, Vermeer M, Cozzio A, Ortiz-Romero P, Bagot M, Olsen E, Kim Y, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Willemze R. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118:4024-35.
Aug 12, 2011EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Aug 12, 2011Blood 2011; 118:4024-35
Kempf Werner, Horwitz Steve, Prince H Miles, Guitart Joan, Estrach Teresa, Sanches José A, Duvic Madeleine, Ranki Annamari, Dreno Brigitte, Ostheeren-Michaelis Sonja, Knobler Robert, Wood Gary, Berti Emilio, Cerroni Lorenzo, Pfaltz Katrin, Vermeer Maarten H, Cozzio Antonio, Ortiz-Romero Pablo L, Bagot Martine, Olsen Elise, Kim Youn H, Dummer Reinhard, Pimpinelli Nicola, Whittaker Sean, Hodak Emmilia, Willemze Rein
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels
Rochlitz C, Dietrich P, Herrmann R, Morant R, Heinzerling L, Escudier B, Baudin M, Acres B, Squiban P, Cavalli F, Jantscheff P, Dreno B, Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer gene therapy 2002; 9:289-95.
Mar 1, 2002Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels
Mar 1, 2002Cancer gene therapy 2002; 9:289-95
Rochlitz Christoph, Dietrich Pierre-Yves, Herrmann Richard, Morant Rudolf, Heinzerling Lucie, Escudier Bernard, Baudin Martine, Acres Bruce, Squiban Patrick, Cavalli Franco, Jantscheff Peter, Dreno Brigitte, Dummer Reinhard